...
首页> 外文期刊>Journal of Natural Medicines >Antihyperlipidaemic activity of swertiamarin, a secoiridoid glycoside in poloxamer-407-induced hyperlipidaemic rats
【24h】

Antihyperlipidaemic activity of swertiamarin, a secoiridoid glycoside in poloxamer-407-induced hyperlipidaemic rats

机译:泊洛沙姆-407诱导的高脂血症大鼠中的蛇形类糖甙-Swertiamarin的抗高脂血症活性

获取原文
获取原文并翻译 | 示例
           

摘要

We have investigated antihyperlipidaemic effect of swertiamarin (50 mg/kg, oral once) isolated from the perennial herb Enicostemma littorale Blume in poloxamer 407 (P-407)-induced hyperlipidaemic rats. Rats were made hyperlipidaemic by intraperitoneal administration of P-407 (400 mg/kg). Serum lipid levels such as total cholesterol, triglycerides and low-density lipoprotein cholesterol increased significantly (P < 0.001) compared with normal control rats. All these changes were significantly prevented in the rats treated with swertiamarin. Serum high-density lipoprotein (HDL) cholesterol was found to be reduced in the P-407 control rats. However, administration of swertiamarin significantly (P < 0.01) increased HDL levels and it showed a significant lipid-lowering effect, as well as a high antiatherogenic potential. Overall swertiamarin is an effective lipid-lowering lead compound and can be useful for preventing atherosclerosis.
机译:我们研究了从多年生草本植物Enicostemma littorale Blume分离出的swertiamarin(50 mg / kg,口服一次)在泊洛沙姆407(P-407)诱导的高脂血症大鼠中的抗高脂血症作用。通过腹膜内施用P-407(400 mg / kg)使大鼠高脂血症。与正常对照组相比,血清脂质水平,例如总胆固醇,甘油三酸酯和低密度脂蛋白胆固醇显着增加(P <0.001)。所有这些变化在用苦参素治疗的大鼠中均得到了明显的预防。在P-407对照大鼠中发现血清高密度脂蛋白(HDL)胆固醇降低。但是,给予swertiamarin(P <0.01)可以显着增加HDL水平,并且显示出显着的降脂作用以及很高的抗动脉粥样硬化潜力。总体而言,swertiamarin是一种有效的降脂先导化合物,可用于预防动脉粥样硬化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号